newsfilter
← Latest News
GlobeNewswire·

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applicationsCompleted a $50 million private placement (PIPE) to further fund clinical development and the portfolio with